TG THERAPEUTICS INC has a total of 39 patent applications. It decreased the IP activity by 87.0%. Its first patent ever was published in 2013. It filed its patents most often in EPO (European Patent Office), United States and China. Its main competitors in its focus markets pharmaceuticals and biotechnology are PSMA DEV COMPANY L L C, YI QING and EMERGO THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 5 | |
#3 | China | 4 | |
#4 | Republic of Korea | 4 | |
#5 | Canada | 3 | |
#6 | Chile | 3 | |
#7 | Mexico | 3 | |
#8 | Singapore | 3 | |
#9 | WIPO (World Intellectual Property Organization) | 3 | |
#10 | Israel | 2 | |
#11 | EAPO (Eurasian Patent Organization) | 1 | |
#12 | Hungary | 1 | |
#13 | New Zealand | 1 | |
#14 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Sportelli Peter | 35 |
#2 | Vakkalanka Swaroop K V S | 20 |
#3 | Weiss Michael | 18 |
#4 | Miskin Hari | 18 |
#5 | Weiss Michael S | 17 |
#6 | Miskin Hari P | 17 |
#7 | Michael S Weiss | 2 |
#8 | Peter Sportelli | 2 |
#9 | Hari P Miskin | 2 |
Publication | Filing date | Title |
---|---|---|
MX2019002728A | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers. | |
EP3150256A1 | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor | |
HUE050878T2 | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |